Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

’Good guy’ blood cells are now suspects in heart disease, diabetes

12.05.2004


Scientists discover a whole new dimension to platelets



Until recently, the story on platelets was pretty simple: tiny blood cells, with limited sophistication because they had no nucleus, and their claim to fame was to be a first-responder to a wound site, to promote healthy clotting and prevent infection. Later scientists theorized platelets might be connected to harmful chronic inflammation, but the links were unclear.

In a paper published in the prestigious scientific journal Blood, a team of University of Rochester researchers opened a new frontier for platelets. They believe the platelet is the pivotal link between inflammation, heart disease and stroke - and may even be a key cell in the body that promotes diabetic complications, the origin of which remains unknown.


Furthermore, the team found that when platelets change from "good guys" to inflammatory villains, they could be doused with a common Type II diabetes drug that was developed to make tissue more insulin sensitive, but acts as an anti-inflammatory agent on platelets. This finding may offer a new way to use anti-diabetic drugs beyond diabetes treatment, or lead to the development of a new generation of drugs that target platelets.

The results came as a laboratory surprise during a broader investigation of platelets and inflammation, led by corresponding author Richard Phipps, Ph.D., University of Rochester Medical Center professor and director of the Lung Biology and Disease Program. Co-authors include Neil Blumberg, M.D., director of the university’s Strong Memorial Hospital Blood Bank and professor of Pathology and Laboratory Medicine; Charles W. Francis, M.D., an authority on vascular disease and a UR professor of Medicine; graduate student Denise Ray, blood bank specialist Kelly F. Gettings, and Filize Akbiyik, M.D., a visiting scientist.

"Our findings totally shift the way we view platelets," Phipps says. "Normally non-nucleated cells have limited capabilities, but we now believe that platelets are far more complex than was thought."

Chronic inflammation is a major concern in medicine. Doctors are trying to understand, for example, why some individuals suffer heart attacks even though they do not have major heart blockages - and inflammation may be the answer. In fact, many chronic cardiovascular diseases suffered by millions of Americans are linked to inflammation, and scientists are rushing to determine which cells are the culprits.

"This new finding has the potential to be a homerun, in the sense that it suggests a new pathway between inflammation and disease," says Blumberg. "But importantly, it’s a pathway that we know already responds to a licensed drug. To use a spring yard work analogy, it’s like realizing one day that although you’ve been using one tool on your lawn, another one hanging in your garage can dramatically contribute to the job, even though no one would suspect it."

Phipps’ lab specializes in investigating the biomarkers for inflammation. In experiments on human platelet samples, they discovered that platelets express PPARg, a transcription factor that was believed to be expressed only by cells with a nucleus. Activation of the PPARg protein by certain anti-diabetic drugs blunts the ability of platelets to release pro-inflammatory mediators and to form clots. Studies are continuing on how PPARg alters platelet function, and the group hopes to launch clinical research to test whether anti-diabetic drugs dampen the inflammatory activity, and can be used to prevent or treat vascular disease.



Funds for the investigation came from the UR; additional grants from the National Institutes of Health are being sought.

Leslie Orr | EurekAlert!
Further information:
http://www.urmc.rochester.edu/

More articles from Life Sciences:

nachricht Superresolution live-cell imaging provides unexpected insights into the dynamic structure of mitochondria
18.02.2020 | Heinrich-Heine-Universität Düsseldorf

nachricht Blood and sweat: Wearable medical sensors will get major sensitivity boost
18.02.2020 | Moscow Institute of Physics and Technology

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Freiburg researcher investigate the origins of surface texture

Most natural and artificial surfaces are rough: metals and even glasses that appear smooth to the naked eye can look like jagged mountain ranges under the microscope. There is currently no uniform theory about the origin of this roughness despite it being observed on all scales, from the atomic to the tectonic. Scientists suspect that the rough surface is formed by irreversible plastic deformation that occurs in many processes of mechanical machining of components such as milling.

Prof. Dr. Lars Pastewka from the Simulation group at the Department of Microsystems Engineering at the University of Freiburg and his team have simulated such...

Im Focus: Skyrmions like it hot: Spin structures are controllable even at high temperatures

Investigation of the temperature dependence of the skyrmion Hall effect reveals further insights into possible new data storage devices

The joint research project of Johannes Gutenberg University Mainz (JGU) and the Massachusetts Institute of Technology (MIT) that had previously demonstrated...

Im Focus: Making the internet more energy efficient through systemic optimization

Researchers at Chalmers University of Technology, Sweden, recently completed a 5-year research project looking at how to make fibre optic communications systems more energy efficient. Among their proposals are smart, error-correcting data chip circuits, which they refined to be 10 times less energy consumptive. The project has yielded several scientific articles, in publications including Nature Communications.

Streaming films and music, scrolling through social media, and using cloud-based storage services are everyday activities now.

Im Focus: New synthesis methods enhance 3D chemical space for drug discovery

After helping develop a new approach for organic synthesis -- carbon-hydrogen functionalization -- scientists at Emory University are now showing how this approach may apply to drug discovery. Nature Catalysis published their most recent work -- a streamlined process for making a three-dimensional scaffold of keen interest to the pharmaceutical industry.

"Our tools open up whole new chemical space for potential drug targets," says Huw Davies, Emory professor of organic chemistry and senior author of the paper.

Im Focus: Quantum fluctuations sustain the record superconductor

Superconductivity approaching room temperature may be possible in hydrogen-rich compounds at much lower pressures than previously expected

Reaching room-temperature superconductivity is one of the biggest dreams in physics. Its discovery would bring a technological revolution by providing...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

70th Lindau Nobel Laureate Meeting: Around 70 Laureates set to meet with young scientists from approx. 100 countries

12.02.2020 | Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

 
Latest News

Movement of a liquid droplet generates over 5 volts of electricity

18.02.2020 | Power and Electrical Engineering

Powering the future: Smallest all-digital circuit opens doors to 5 nm next-gen semiconductor

18.02.2020 | Information Technology

Studying electrons, bridging two realms of physics: connecting solids and soft matter

18.02.2020 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>